Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.
Conditions
Interventions
BL-M11D1
Locations
14
United States
City of Hope
Duarte, California, United States
UCLA Ronald Reagan Medical Center
Los Angeles, California, United States
Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut, United States
Moffitt Cancer Center
Tampa, Florida, United States
START Midwest/The Cancer and Hematology Center
Grand Rapids, Michigan, United States
Oncology Hematology Care Clinical Trials, LLC
Cincinnati, Ohio, United States
Start Date
December 19, 2024
Primary Completion Date
December 31, 2026
Completion Date
March 30, 2027
Last Updated
December 31, 2025
NCT07523555
NCT05143996
NCT05924750
NCT06869265
NCT06541405
NCT06049667
Lead Sponsor
SystImmune Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions